Abhimanyu Mandal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abhimanyu Mandal has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Arun Khattri
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India
1 shared publication - Aryaman Joshi
Department of Chemical Engineering and Technology, Indian Institute of Technology, Banaras Hindu University, Varanasi 221005, India
1 shared publication - Neeraj Jain
Division of Cancer Biology, CSIR-Central Drug Research Institute, Lucknow, India
1 shared publication - Ravi Shanker Srivastava
Department of Pharmacology, Career Institute of Medical Sciences & Hospital, Lucknow 226020, India
1 shared publication - Sagorika Nag
UC Santa Cruz Genomics Institute, Santa Cruz, CA, USA
1 shared publication - Sanjay Singh
Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow 226025, India
1 shared publication
Latest Publications
- Open Access
Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment
Cancers are the leading cause of death, causing around 10 million deaths annually by 2020. The most common cancers are those affecting the breast, lungs, colon, and rectum. However, it has been noted that cancer metastasis is more lethal than just cancer incidence and accounts for more than 90% of cancer deaths. Thus, early detection and prevention of cancer metastasis have the capability to save millions of lives. Finding novel biomarkers and targets for screening, determination of prognosis, targeted therapies, etc., are ways of doing so. In this review, we propose various sialyltransferases and neuraminidases as potential therapeutic targets for the treatment of the most common cancers, along with a few rare ones, on the basis of existing experimental and in silico data. This compilation of available cancer studies aiming at sialyltransferases and neuraminidases will serve as a guide for scientists and researchers working on possible targets for various cancers and will also provide data about the existing drugs which inhibit the action of these enzymes.
Open AccessSialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment
Cancers are the leading cause of death, causing around 10 million deaths annually by 2020. The most common cancers are those affecting the breast, lungs, colon, and rectum. However, it has been noted that cancer metastasis is more lethal than just cancer incidence and accounts for more than 90% of cancer deaths. Thus, early detection and prevention of cancer metastasis have the capability to save millions of lives. Finding novel biomarkers and targets for screening, determination of prognosis, targeted therapies, etc., are ways of doing so. In this review, we propose various sialyltransferases and neuraminidases as potential therapeutic targets for the treatment of the most common cancers, along with a few rare ones, on the basis of existing experimental and in silico data. This compilation of available cancer studies aiming at sialyltransferases and neuraminidases will serve as a guide for scientists and researchers working on possible targets for various cancers and will also provide data about the existing drugs which inhibit the action of these enzymes.